MaxCyte fundraising was oversubscribed

News

01/05/20

Panmure Gordon acted as nominated adviser, joint broker and joint bookrunner for MaxCyte’s successful £25.1 million fundraising. The funds will be used to accelerate and strengthen the company’s global leadership in non-viral cell engineering by building balance sheet strength as it looks ahead to a Nasdaq IPO.

The offering was led by Casdin Capital, a US life science-focused investment firm, and Sofinnova Partners, a European life sciences investment firm.

Freddy Crossley, Panmure Gordon’s Head of Healthcare, said: “We are delighted to continue to support MaxCyte’s development plans and were pleased to have two specialist healthcare funds join the high quality list of existing shareholders, in this challenging market.”

The transaction follows the successful private placement last week for Faron Pharmaceuticals, which raised EUR14 million and for which Panmure Gordon was sole UK bookrunner and corporate broker. Panmure Gordon also acted as sole broker and nominated adviser for Inland Homes’ successful £10 million fundraising.

MaxCyte fundraising was oversubscribed

Other insights like this

Thirsty football fans helped to prop up struggling UK economy during World Cup

Three Lessons From a Recession That Never Was

Britain Is Too Cheap for Retail Investors to Ignore

BAT investors call on tobacco group’s new chief to restart share buybacks

NWF Group posts record interim results, despite turbulent trading conditions

Acted as Rule 3 Adviser, Joint Financial Adviser and Joint Broker to CareTech Holdings

Joint Broker Appointment to AMTE Power plc

Rule 3 Adviser and Financial Adviser for CT Property Trust Limited